Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

NCT05347095 is registered in ClinicalTrials.gov with Janssen-Cilag Ltd. as lead sponsor.

NCT NCT05347095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05347095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
Lead sponsor
Janssen-Cilag Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 27, 2022
Completion date
March 25, 2027
Enrollment
288 (actual)
Sites
154

Conditions

As the registry lists them; a condition with its own page is linked.

fistulizing crohns disease, perianal crohns disease